Office management of COPD in primary care: A 2009 clinical update

Postgraduate Medicine

Volumn 121, Issue 4, 2009, Pages 82-90

  Belfer, Mark H ^a,b  

^a Akron General Partners Physician Group   (United States)

^b AKRON GENERAL MEDICAL CENTER   (United States)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Dyspnea; Spirometry; Tobacco smoking

Indexed keywords

AMFEBUTAMONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; HEMOGLOBIN; INFLUENZA VACCINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; PNEUMOCOCCUS VACCINE; SALBUTAMOL; SHORT ACTING DRUG; TIOTROPIUM BROMIDE; VARENICLINE;

ABNORMAL RESPIRATORY SOUND; ADULT; AEROBIC EXERCISE; ARTICLE; ASTHMA; BLOOD PRESSURE; BODY HEIGHT; BODY WEIGHT; BREATHING RATE; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COUGHING; COUNSELING; DEPRESSION; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DYSPNEA; ELECTROCARDIOGRAPHY; ERYTHROCYTE COUNT; EXERCISE TOLERANCE; FATIGUE; FEMALE; FOLLOW UP; HEART RATE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERINFLATION; INFLUENZA VACCINATION; INHALER; LEUKOCYTE COUNT; MEDICATION ERROR; MOUTH BREATHING; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PROGNOSIS; QUALITY OF LIFE; SCREENING; SINUS CONGESTION; SMOKING; SMOKING CESSATION; SPIROMETRY; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; WITHDRAWAL SYNDROME;

BRONCHODILATOR AGENTS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MIDDLE AGED; OFFICE VISITS; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SPIROMETRY;

EID: 68149159897     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.07.2034     Document Type: Article

References (32)

1. Celli BR, MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patiens with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-946.
2. O'Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendation for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. Can Respir J. 2008;15(suppl A):1A-8A. (Pubitemid 351566057)
3. U.S. Preventive Services Task Force. Screening for chronic obstructive pulmonary disease using spirometry: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;148(7):529-534.
4. Global Strategy for the Diagnosis, Management, and Preventive of COPD (Updated 2008). Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). http://www.goldcopd.com. Accessed 24 June, 2009.
5. Fletcher C, Peto R. The natural histosy of chronic airflow obstruction. Br Med J. 1977;1(6077):1645-1648. (Pubitemid 8124466)
6. Lundbäck B, Lindberg A, Lindström M, et al; Obstructive Lung Disease in Northern Sweden Studies. Not 15 but 50% of smokers develop COPD? - Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med. 2003;97(2):115-122.
7. Chen Y, Breithaupt K, Muhajarine N. Occurrence of chronic obstructive pulmonary disease among Canadians and sex-related risk factors. J Clin Epidemiol. 2000;53(7):755-761. (Pubitemid 30609630)
8. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. MMWR Surveill Summ. 2002;51(6):1-16.
9. Centers for Disease Control (CDC). Smoking and health: a national status report. MMWR Morb Mortal Wkly Rep. 1986;35(46):709-711.
10. Vonk JM, Jougepier H, Panhuysen CI, Schouten JP, Bleecker ER, Postma DS. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax. 2003;58(4):322-327.
11. Mosenifar Z. Differentiating COPD from asthma in clinical practice. Postgrad Med. 2009;121(3):105-112.
12. Martinez FJ, Raczek AE, Seifer FD, et al: COPD-PS Clinician Working Group. Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS). COPD. 2008;5(2):85-145
13. Price DB, Tinkelman DG, Halbert RJ, et al. Symptom-based questionnaire for identifying COPD in smokers. Respiration. 2006;73(3):285-295.
14. Tinkelman DG, Price DB, Nordyke RJ, et al. Symptom-based questionnaire for differentiating COPD asthma. Respiration. 2006;73(3):296-305. (Pubitemid 43725786)
15. Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ. Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. J Asthma. 2006;43(1):75-80. (Pubitemid 43916347)
16. Calverley PM, Anderson JA, Celli, B, et al: TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Eng J Med. 2007;356(8):775-789.
17. Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ. 2008;336(7644):598-600.
18. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J. 1959;2(5147):257-266.
19. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA. 2000;283(24):3244-3254.
20. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomized trial. Lancet. 2001;357(9268):1571-1575. (Pubitemid 32488814)
21. Wagena EJ, Knipschild PG, Huibers MJ, Wouters EF, van Schayek CP. Efficacy of bupropion and notriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med. 2005;165(19):2286-2292. (Pubitemid 41549926)
22. Gonzales D, Rennard SI, Nides M, et al: Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47-55.
23. Jorenby DE, Hays JT, Rigotti NA, et al: Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;266:56-63.
24. Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR; Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):64-71.
25. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006;166(15):1561-1568. (Pubitemid 44232363)
26. Williams KE, Reeves KR, Billing CB, Jr, Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin. 2007;23(4):793-801. (Pubitemid 46646499)
27. Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther. 2007;29(6):1027-1039.
28. Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of verenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther. 2007;29(6):1040-1056. (Pubitemid 47198885)
29. Nides M, Glover ED, Reus VI, et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav. 2008;32(6):664-675.
30. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomized open-label trial. Thorax. 2008;63(8):717-724.
31. Radin A, Cote C. Primary care of the patient with chronic obstructive pulmonary disease-part 1: frontline prevention and early diagnosis. Am J Med. 2008;121(7 suppl):S3-S12. (Pubitemid 351858559)
32. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169(3):219-229.